Leading companies and knowledge agents in health R & D & I, manufacturing and knowledge generators
New specialised training programmes with the participation of 15 companies
Submitted competitive projects
Activities with nearly 1,000 attendees
55% of member companies and institutions in health entrepreneurship
100% representation in the territory and representation of the transversality in the health sector
17 October 2024
The leading international group in the production of pharmaceutical active ingredients Moehs, member of CATALONIA.HEALTH, has signed an exclusive agreement with EUROAPI to assume the production of Metamizol, the active ingredient of the drug Nolotil, in its facilities in Spain.
16 October 2024
A worldwide leader in specialized diagnostics Werfen, member of CATALONIA. HEALTH, announces the finalization of a partnership agreement with Seegene Inc. Under the agreement, Seegene and Werfen will set up a NewCo in Spain, Werfen-Seegene, upon the conclusion of mandatory government approvals anticipated by the first half of 2025.
16 October 2024
The company dedicated to personalized medicine Inbiomotion, member of CATALONIA.HEALTH, have signed an exclusive agreement to start offering the MAF Test® in Italy.
14 October 2024
The biopharmaceutical company Oryzon Genomics, member of CATALONIA.HEALTH, announces that it has received the official record of its recent meeting of End-of-Phase II for vafidemstaten for Personality Limit Disorder (TLP) with the US Food and Drug Administration (FDA). ORYZON will begin the preparation of a complete protocol for the study of Phase III PORTICO-2 that will soon be presented to the FDA for approval.
14 October 2024
The UMBRELLA consortium, led by Vall d'Hebron Research Institute (VHIR), a member of CATALONIA.HEALTH, and the company Siemens Healthineers, is made up of more than 20 public and private partners whose objective is to revolutionize the entire stroke care process in Europe.
9 October 2024
The biotechnology company Archivel Farma, a member of CATALONIA.HEALTH, announces the opening of a business line as the Contract Development and Manufacturing Organization (CDMO). The initiative will focus on the manufacture of clinical batches under Good Manufacturing Practices (GMP).
7 October 2024
The pharmaceutical company Almirall, member of CATALONIA.HEALTH, launches the new Ebglyss treatment (lebrikizumab) in Spain. This monoclonal antibody is already available for the treatment of adult and teen patients with atopic dermatitis from moderate to severe and who are candidates for systemic therapy.
4 October 2024
The “deeptech” and leading bioinformatics company Sequentia Biotech, member of CATALONIA.HEALTH, obtains a €10 million Series A investment, which is led by Seventure Partners, and co-invested by the EIC Fund. The investment will accelerate Sequentia Biotech’s mission to drive innovation in the field of omics.
30 September 2024
INBRAIN Neuroelectronics, member of CATALONIA.HEALTH, has announced the world's first application of a graphene interface in a human patient. This intervention was performed on a patient undergoing resection (removal) of a brain tumor. The company is a spin-off of ICN2 and CSIC.
30 September 2024
The pioneering company in the life sciences venture capital sector Asabys Partner, member of CATALONIA.HEALTH, announced today the successful final close of its second fund, Sabadell Asabys Health Innovation Investments II (SAHII II) with total commitments of €180 million ($200M), exceeding its initial target of €150 million.
Keep up to date with the latest news from CataloniaBio & HealthTech! News, Activities, Events ... Join now!!